Insmed reports fourth quarter and full year 2022 financial results and provides business update

—patient screening complete in adult patients in phase 3 aspen trial of brensocatib in bronchiectasis; topline data readout on track for second quarter of 2024— —company to share robust updates across early-stage programs at research day on may 8, 2023— —company on track to share topline data from post-marketing arise study of arikayce® (amikacin liposome inhalation suspension) in third quarter of 2023— —arikayce total revenue of $59.3 million for the fourth quarter and $ 245.4  million for the full year 2022, reflecting 30% annual growth— bridgewater, n.j. , feb. 23, 2023 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended december 31, 2022 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking